Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
EHC Stock Summary
Top 10 Correlated ETFs
EHC
In the News
Encompass Health (EHC) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Encompass Health (EHC) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Encompass Health (EHC) Up 42% in a Year: What Lies Ahead?
Encompass Health (EHC) remains well-poised for growth on the back of sustained top-line growth, an expanding healthcare facility portfolio and robust cash-generating abilities.
An In-Depth Analysis of Encompass Health's (EHC) 2024 Outlook
Growth in Medicare and Managed Care pricing, along with capacity additions of six de novos with 280 beds, will likely have an impact on Encompass Health's (EHC) 2024 bottom line.
Encompass Health (EHC), Piedmont to Build Loganville Facility
Encompass Health (EHC) partners with Piedmont to construct a 40-bed inpatient rehabilitation hospital in Georgia to better serve the rehabilitative care needs of the state and solidify its footprint.
Here's Why Encompass Health (EHC) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Encompass Health to present at Barclays Global Healthcare Conference
BIRMINGHAM, Ala. , March 5, 2024 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will participate in the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 12-14, 2024.
Encompass Health (EHC) Upgraded to Buy: What Does It Mean for the Stock?
Encompass Health (EHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Encompass Health (EHC) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
4 Stocks to Watch in a Resilient Outpatient Home Health Industry
The rising dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DVA, EHC, OPCH and ADUS are well-poised to gain.
EHC Financial details
EHC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 46.99 | 47.1 | 51.73 | 43.84 | 48.25 | |
Net income per share | 3.66 | 2.88 | 4.16 | 2.73 | 3.54 | |
Operating cash flow per share | 6.48 | 7.15 | 7.23 | 7.11 | 8.55 | |
Free cash flow per share | 2.36 | 3.01 | 1.66 | 1.23 | 2.69 | |
Cash per share | 0.97 | 2.27 | 0.55 | 0.22 | 1.43 | |
Book value per share | 13.8 | 16.11 | 19.31 | 13.21 | 16.56 | |
Tangible book value per share | -8.66 | -7.59 | -4.51 | 3.19 | 7.41 | |
Share holders equity per share | 13.8 | 16.11 | 19.31 | 13.21 | 16.56 | |
Interest debt per share | 35.78 | 37.8 | 37.4 | 31.94 | 25.88 | |
Market cap | 5.4B | 6.49B | 5.14B | 5.93B | 6.64B | |
Enterprise value | 8.65B | 9.81B | 8.62B | 8.9B | 9.47B | |
P/E ratio | 15.06 | 22.82 | 12.47 | 21.89 | 18.86 | |
Price to sales ratio | 1.17 | 1.4 | 1 | 1.36 | 1.38 | |
POCF ratio | 8.5 | 9.2 | 7.18 | 8.41 | 7.8 | |
PFCF ratio | 23.36 | 21.87 | 31.23 | 48.75 | 24.8 | |
P/B Ratio | 3.99 | 4.08 | 2.69 | 4.53 | 4.03 | |
PTB ratio | 3.99 | 4.08 | 2.69 | 4.53 | 4.03 | |
EV to sales | 1.88 | 2.11 | 1.68 | 2.05 | 1.97 | |
Enterprise value over EBITDA | 9.12 | 10.84 | 7.99 | 10.22 | 9.41 | |
EV to operating cash flow | 13.62 | 13.91 | 12.05 | 12.61 | 11.13 | |
EV to free cash flow | 37.43 | 33.07 | 52.39 | 73.16 | 35.37 | |
Earnings yield | 0.07 | 0.04 | 0.08 | 0.05 | 0.05 | |
Free cash flow yield | 0.04 | 0.05 | 0.03 | 0.02 | 0.04 | |
Debt to equity | 2.48 | 2.23 | 1.85 | 2.28 | 1.47 | |
Debt to assets | 0.55 | 0.55 | 0.52 | 0.53 | 0.4 | |
Net debt to EBITDA | 3.43 | 3.67 | 3.23 | 3.41 | 2.81 | |
Current ratio | 1.05 | 1.32 | 1.23 | 1.25 | 1.28 | |
Interest coverage | 4.57 | 3.59 | 5 | 3.57 | 4.66 | |
Income quality | 1.42 | 1.91 | 1.38 | 1.93 | 2.35 | |
Dividend Yield | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | |
Payout ratio | 0.3 | 0.39 | 0.27 | 0.37 | 0.17 | |
Sales general and administrative to revenue | 0.63 | 0.63 | 0.62 | 0.6 | 0.6 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.46 | 0.43 | 0.41 | 0.27 | 0.26 | |
Capex to operating cash flow | -0.64 | -0.58 | -0.77 | -0.83 | -0.69 | |
Capex to revenue | -0.09 | -0.09 | -0.11 | -0.13 | -0.12 | |
Capex to depreciation | -1.85 | -1.68 | -2.15 | -2.4 | -2.13 | |
Stock based compensation to revenue | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | |
Graham number | 33.71 | 32.32 | 42.53 | 28.49 | 36.3 | |
ROIC | 0.12 | 0.1 | 0.11 | 0.11 | 0.12 | |
Return on tangible assets | 0.11 | 0.08 | 0.1 | 0.07 | 0.08 | |
Graham Net | -37.19 | -38.11 | -39.07 | -33.61 | -32.21 | |
Working capital | 34.8M | 231.3M | 172.6M | 141.3M | 185.4M | |
Tangible asset value | -848.8M | -748.4M | -446.2M | 316.4M | 737.7M | |
Net current asset value | -3.39B | -3.5B | -3.54B | -3.06B | -2.96B | |
Invested capital | 2.48 | 2.23 | 1.85 | 2.28 | 1.47 | |
Average receivables | 486.9M | 539.45M | 626.55M | 608.55M | 574.2M | |
Average payables | 92.3M | 104.8M | 126.3M | 135.25M | 151.45M | |
Average inventory | 58.2M | 61.4M | 65.25M | 48.35M | 15.8M | |
Days sales outstanding | 40.11 | 45.02 | 48.48 | 45.06 | 46.5 | |
Days payables outstanding | 205.65 | 209.35 | 239.96 | 240.02 | 16.04 | |
Days of inventory on hand | 124.78 | 119.06 | 113.53 | 57.07 | 0 | |
Receivables turnover | 9.1 | 8.11 | 7.53 | 8.1 | 7.85 | |
Payables turnover | 1.77 | 1.74 | 1.52 | 1.52 | 22.75 | |
Inventory turnover | 2.93 | 3.07 | 3.22 | 6.4 | 0 | |
ROE | 0.27 | 0.18 | 0.22 | 0.21 | 0.21 | |
Capex per share | -4.12 | -4.14 | -5.57 | -5.89 | -5.86 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 11.45 | 11.67 | 11.93 | 12.13 | 12.53 | |
Net income per share | 0.9 | 0.88 | 0.92 | 0.86 | 0.88 | |
Operating cash flow per share | 1.73 | 2.29 | 2.08 | 2.16 | 2.02 | |
Free cash flow per share | -0.3 | 1.32 | 0.9 | 0.69 | -0.22 | |
Cash per share | 0.22 | 1.15 | 1.51 | 1.38 | 1.43 | |
Book value per share | 13.2 | 13.92 | 14.83 | 15.68 | 16.56 | |
Tangible book value per share | 3.19 | 4.08 | 5.11 | 6.35 | 7.41 | |
Share holders equity per share | 13.2 | 13.92 | 14.83 | 15.68 | 16.56 | |
Interest debt per share | 30.51 | 30.29 | 29.9 | 29.76 | 24.65 | |
Market cap | 5.94B | 5.38B | 6.74B | 6.68B | 6.64B | |
Enterprise value | 8.91B | 8.27B | 9.56B | 9.51B | 9.47B | |
P/E ratio | 16.61 | 15.33 | 18.43 | 19.59 | 18.95 | |
Price to sales ratio | 5.22 | 4.63 | 5.68 | 5.54 | 5.32 | |
POCF ratio | 34.49 | 23.6 | 32.59 | 31.05 | 33.03 | |
PFCF ratio | -201.33 | 40.96 | 75.28 | 97.55 | -307.34 | |
P/B Ratio | 4.53 | 3.89 | 4.57 | 4.28 | 4.03 | |
PTB ratio | 4.53 | 3.89 | 4.57 | 4.28 | 4.03 | |
EV to sales | 7.83 | 7.12 | 8.05 | 7.88 | 7.59 | |
Enterprise value over EBITDA | 35.4 | 33.54 | 36.75 | 38.31 | 36.41 | |
EV to operating cash flow | 51.74 | 36.27 | 46.24 | 44.18 | 47.1 | |
EV to free cash flow | -302.02 | 62.96 | 106.8 | 138.8 | -438.3 | |
Earnings yield | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | |
Free cash flow yield | 0 | 0.02 | 0.01 | 0.01 | 0 | |
Debt to equity | 2.28 | 2.15 | 1.99 | 1.87 | 1.47 | |
Debt to assets | 0.53 | 0.52 | 0.5 | 0.49 | 0.4 | |
Net debt to EBITDA | 11.8 | 11.72 | 10.85 | 11.38 | 10.88 | |
Current ratio | 1.25 | 1.29 | 1.26 | 1.27 | 1.28 | |
Interest coverage | 5.02 | 5.02 | 3.26 | 3.19 | 5.44 | |
Income quality | 1.47 | 1.99 | 1.75 | 1.88 | 2.09 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0.17 | 0.18 | 0.16 | 0.18 | 0.17 | |
Sales general and administrative to revenue | 0.59 | 0.59 | 0.59 | 0.6 | 0.04 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.27 | 0.27 | 0.26 | 0.26 | 0.26 | |
Capex to operating cash flow | -1.17 | -0.42 | -0.57 | -0.68 | -1.11 | |
Capex to revenue | -0.18 | -0.08 | -0.1 | -0.12 | -0.18 | |
Capex to depreciation | -3.19 | -1.51 | -1.61 | -2.18 | -3.18 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Graham number | 16.35 | 16.62 | 17.51 | 17.39 | 18.11 | |
ROIC | 0.03 | 0.03 | 0.02 | 0.02 | 0.03 | |
Return on tangible assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Graham Net | -33.58 | -32.86 | -32.52 | -32.32 | -32.21 | |
Working capital | 141.3M | 169.6M | 169M | 174.5M | 185.4M | |
Tangible asset value | 316.4M | 405.3M | 508.2M | 631.5M | 737.7M | |
Net current asset value | -3.06B | -3.02B | -2.98B | -2.96B | -2.96B | |
Invested capital | 2.28 | 2.15 | 1.99 | 1.87 | 1.47 | |
Average receivables | 518.45M | 525.65M | 523.4M | 534.1M | 573.75M | |
Average payables | 133.5M | 137M | 148.45M | 160.6M | 167.7M | |
Average inventory | 37.95M | 32.95M | 35.4M | 39M | 20.75M | |
Days sales outstanding | 42.48 | 39.9 | 40.36 | 39.96 | 44.15 | |
Days payables outstanding | 221.91 | 236.04 | 269.65 | 276.18 | 15.24 | |
Days of inventory on hand | 52.76 | 57.38 | 63.17 | 69.29 | 0 | |
Receivables turnover | 2.12 | 2.26 | 2.23 | 2.25 | 2.04 | |
Payables turnover | 0.41 | 0.38 | 0.33 | 0.33 | 5.9 | |
Inventory turnover | 1.71 | 1.57 | 1.42 | 1.3 | 0 | |
ROE | 0.07 | 0.06 | 0.06 | 0.05 | 0.05 | |
Capex per share | -2.03 | -0.97 | -1.18 | -1.47 | -2.24 |
EHC Frequently Asked Questions
What is Encompass Health Corporation stock symbol ?
Encompass Health Corporation is a US stock , located in Birmingham of Al and trading under the symbol EHC
Is Encompass Health Corporation buy or a sell ?
4 stock analysts have 4 predictions with a medium analyst target price of $88.25. The lowest prediction is $83 and the highest is $100
What is EHC stock prediction ?
What is Encompass Health Corporation stock quote today ?
Encompass Health Corporation stock price is $82.32 today.
Is Encompass Health Corporation stock public?
Yes, Encompass Health Corporation is a publicly traded company.